GENELUX Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the three months ended September 30, 2025, the following officer (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities as set forth in the table below.
| Name and Position | Action | Date | Rule 10b5-1* | Expiration Date | Total Number of Securities to be Sold |
|---|---|---|---|---|---|
| Yong (Tony) Yu, SVP Clinical Development | Adoption | 09/16/2025 | X | 12/16/2026 | Up to 67,356 shares |
*Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.